Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab

This article was originally published here

Ibrutinib, a once-a-day drug that is administered orally, inhibits the first-in-class Bruton’s tyrosine kinase (BTK) that sends crucial signals to B cells to mature and produce antibodies, said

The post Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply